HERG Screening Market End user , Supply Distributors | Analysis Market and Trend
HERG Screening Market Analysis Overview:
The
HERG (human ether-a-go-go-related gene) screening market is a critical
segment within preclinical drug development. HERG channels are potassium ion
channels in the heart, and their blockage by drug candidates can lead to
potentially fatal cardiac arrhythmias, specifically Torsade de Pointes. HERG
screening services and technologies are essential for assessing the cardio
toxic potential of new drugs, ensuring patient safety, and complying with
regulatory requirements.
Key Drivers:
·
Stringent Regulatory Requirements: Regulatory
agencies, such as the FDA and EMA, mandate HERG channel testing as a crucial
part of preclinical drug safety assessment.
·
Increased Focus on Drug Safety: The growing
awareness of drug-induced cardiotoxicity and the need to minimize risks to
patients are driving demand for HERG screening services.
·
Advancements in Screening Technologies: The
development of more sensitive, reliable, and high-throughput HERG screening
methods is improving the efficiency and accuracy of drug safety testing.
·
Rising R&D Investments in Pharmaceuticals:
Increasing investments in pharmaceutical research and development, particularly
in areas like oncology and cardiovascular diseases, are driving demand for
preclinical safety testing, including HERG screening.
·
Growing Demand for Contract Research
Organizations (CROs): Pharmaceutical companies are increasingly outsourcing
preclinical safety testing to CROs, which specialize in HERG screening and
other safety assessment services.
·
Atrial fibrillation is a cardiac arrhythmia
characterized by irregular and rapid heartbeat which leads to stroke, heart
failure and other cardiovascular complications. HERG screening is widely used
in the treatment of atrial fibrillation as it ensures the development of safe
and effective antiarrhythmic drugs without any cardiotoxicity.
Key Restraints:
·
High Cost of HERG Screening: HERG screening can
be expensive, particularly for complex studies and high-throughput screening.
·
Technical Challenges: HERG channel assays can be
technically challenging, requiring specialized expertise and equipment.
·
Variability in Assay Results: Variability in
assay results due to differences in cell lines, protocols, and equipment can
pose challenges for data interpretation and comparison.
·
Ethical Concerns Related to Animal Testing: Some
HERG screening methods involve animal testing, which raises ethical concerns
and may face increasing scrutiny.
·
Stringent rules and regulations are constraining
the market due to differing requirements for HERG screening across various
regulatory bodies like United States Food & Drug Administration, European
Medicines Agency, and others.
·
Additionally, regulatory changes or updates in
guidelines result in increased cost in the drug development.
Future Opportunities:
·
Development of Alternative Screening Methods:
The development of alternative screening methods, such as in silico
modelling, stem cell-based assays, and microfluidic platforms, can reduce
reliance on animal testing and improve efficiency.
·
Automation and High-Throughput Screening: The
automation of HERG screening assays and the development of high-throughput
platforms can increase efficiency and reduce costs.
·
Personalized Medicine and Drug Safety: The
application of personalized medicine approaches to HERG screening can help
identify individuals at higher risk of drug-induced cardiotoxicity.
·
Expansion into Emerging Markets: The growing
pharmaceutical industry in emerging markets, such as Asia-Pacific and Latin
America, presents significant growth opportunities for HERG screening service
providers.
·
Development of Improved Cell Lines and Assays:
The development of improved cell lines and assays that better mimic human
cardiac physiology can enhance the accuracy and reliability of HERG screening.
·
HERG assay is used to evaluate a compound
potential to block the HERG potassium channel, which plays a critical role in
cardiac repolarization and arrhythmia prevention. This assay plays an important
role in HERG screening which measures whether a drug blocks or interferes with
the HERG channel.
Segmentation:
The HERG screening market can be segmented based on:
·
Technology: Automated patch clamp, manual patch
clamp, fluorescence-based assays, in silico modelling.
·
Service Type: Standalone HERG screening, integrated
drug safety testing.
·
End-User: Pharmaceutical companies,
biotechnology companies, contract research organizations (CROs), academic
institutions.
·
Region: North America, Europe, Asia-Pacific,
Latin America, Middle East & Africa.
Key Players:
Major players in the HERG screening market include:
·
Charles River Laboratories (United States)
·
Thermo Fisher Scientific Inc. (United States)
·
Creative Biolabs (United States)
·
Aurora Biomed Inc. (Canada)
·
AstraZeneca (United Kingdom)
·
ChanTest Corporation (United States)
·
AVIVA Biosciences (United States)
·
BSYS GmbH (Switzerland)
·
Caliper (United States)
·
Aureus Sciences (France)
Regional Analysis:
North America: A significant market with a strong presence
of pharmaceutical and biotechnology companies and advanced research
infrastructure.
Europe: A mature market with stringent regulatory
requirements and a focus on research and development.
Asia-Pacific: A rapidly growing market driven by increasing
pharmaceutical R&D investments and the expansion of CROs.
Recent Developments:
Include recent developments in the market, such as new
technological advancements, collaborations, mergers and acquisitions, and
regulatory updates. This information will require ongoing research and updates.
In 2023, Metrion Biosciences launched HERG screening
service. It is available with Good Laboratory Practice compliance which is
essential in drug formulations with cardiac safety.
Other Related
Reports:
Bloodstream
Infection Testing Market
Comments
Post a Comment